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model from the perspective of a US private insurance payer to evaluate the cost-
effectiveness of rituximab, tacrolimus, and cyclosporine in a hypothetical cohort 
of 1,000 patients with refractory MG, aged 20 years and above. We obtained dis-
ease transition probabilities, costs and outcomes data from the published litera-
ture. We calculated the incremental cost-effectiveness ratios (ICERs) as cost per 
quality-adjusted life-year (QALY) gained and cost per myasthenic crisis averted 
after the first two years of treatment and over a patient’s lifetime. RESULTS: In 
the first two years after treatment rituximab is not cost-effective compared with 
cyclosporine, given an ICER of $368,823 per QALY gained. However, over a patient’s 
lifetime rituximab has an ICER of $41,947 per QALY gained making it more cost-
effective than cyclosporine in the context of the commonly accepted US thresh-
old of $50,000 per QALY gained. Tacrolimus is more costly and less effective 
than cyclosporine and rituximab both after two years of treatment and over a 
 patient’s lifetime. CONCLUSIONS: Assuming the benefits of treatment persist over 
time, rituximab is more cost-effective than cyclosporine over a patient’s lifetime but 
not after two years of treatment under both the standard US threshold of $50,000 
per QALY gained and an alternative higher threshold of $100,000 per QALY gained. 
Additional research is needed to evaluate the long-term benefits of rituximab.
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OBJECTIVES: Nearly 54 million Medicare beneficiaries, the overwhelming majority 
of whom are 65 plus years of age, reside in the US. Many beneficiaries suffer from 
chronic pain and need to use opioid analgesics for treatment. Medicare Part D is 
the outpatient prescription drug benefit available to beneficiaries through private 
insurance companies. Plan offerings differ across the country and each plan can 
have a different cost-sharing structure and formulary. We sought to examine the 
cost differences between therapeutically equivalent doses of opioid analgesics 
across all Medicare Part D Stand-alone prescription drug plans (PDPs). METHODS: 
Five short- and five long-acting opioid analgesic drugs were selected based on 
their prevalence of use and effectiveness at treating chronic pain. Therapeutically 
equivalent doses of each drug were entered into the Medicare Plan Finder Tool 
(www.medicare.gov) and 2015 data from 965 PDPs in 34 Medicare regions across the 
country were recorded. Collected data for each drug included: full cost, expected 
out-of-pocket costs both in a retail and mail order setting, and cost at a stand-
ard and preferred network pharmacy. RESULTS: Full annual retail drug costs var-
ied from a low of $134.42 (Methadone 5mg; thrice daily) to a high of $10,443.30 
(Hydromorphone ER 16mg; once daily). Beneficiary cost-sharing of the full annual 
drug costs in a retail pharmacy ranged from 36% (Hydrocodone 5/325; 12 tabs daily) 
to 93% (Hydromorphone ER). The annual out-of-pocket costs through mail order 
were between 88% (Oxycodone 5mg; 8 tabs daily) and 102% (Morphine 30mg; 2 
tabs daily) of the costs in a retail pharmacy setting. Beneficiary out-of-pocket costs 
for the same drug was between 7% and 44% cheaper at a preferred network phar-
macy as compared to a standard network pharmacy. CONCLUSIONS: Considerable 
cost variability exists among equipotent opioid analgesics across Medicare PDPs. 
Minimizing beneficiary out-of-pocket costs may improve economic outcomes with-
out sacrificing clinical outcomes.
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OBJECTIVES: Ivacaftor is a breakthrough treatment for cystic fibrosis (CF) patients 
with the G551D genetic mutation. Clinical trials show ivacaftor significantly 
improves lung function. Information on lifetime clinical effects and cost are lacking. 
This study aims to forecast lifetime outcomes and cost by comparing ivacaftor plus 
usual care versus usual care alone. METHODS: A lifetime Markov model of ivacaftor 
for G551D mutation CF patients aged ≥ 6 years was conducted from a United States 
payer perspective. The model consisted of 5 health states: 1) forced expiratory vol-
ume 1-second (FEV1) % predicted > 70%, 2) 40%≤ FEV1≤ 70%, 3) FEV1< 40%, 4) Lung 
transplantation, and 5) Death. All inputs were determined by literature sources. 
Efficacy of ivacaftor was from previous randomized clinical trials for the first 2 years. 
The efficacy after 2 years was assumed half of the observed efficacy (consistent 
with United Kingdom assessment assumption). The budget impact was estimated. 
We indirectly estimated ivacaftor’s improvement in CF outcome gaps compared 
to the non-CF population. RESULTS: Compared to the usual care alone, ivacaftor 
treatment was associated with 18.09 additional life-years [(95% credible interval 
(CI); 14.63-21.13] and 14.92 additional quality-adjusted life-years (QALYs) [95%CI; 
11.92 – 17.95] over an average lifetime. Moving from usual care alone to ivacaftor 
treatment was associated with reducing the survival and QALY gaps of the non-CF 
population by 52.32% and 44.29%, respectively. The incremental lifetime cost with 
3% discount was $3,740,480. The budget impact was $0.09 per-member per-month 
[95% CI; $0.07 to $0.11]. CONCLUSIONS: Ivacaftor was forecasted to increase life-
years and QALYs in CF patients with the G551D mutation and move morbidity 
and mortality outcomes closer to that of their non-CF peers. The overall cost in 
patients with ivacaftor is much higher than usual care, but comes at a relatively low 
budget impact. Uncertainty in this literature-informed analysis could be reduced 
with patient-level analyses.
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sensitivity analyses indicates that for these comparisons, based on a threshold of 
£20,000, Movantik has a respective probability of 91%, 83% and 100% of being cost 
effective. In a population of LIR patients who are taking step 3 opioids, Movantik is 
dominant vs. Targin over a 5 year time horizon. CONCLUSIONS: Movantik is a cost-
effective treatment option for patients with OIC who have experienced inadequate 
response to laxative(s).
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OBJECTIVES: Limbal Stem Cell Deficiency (LSCD) is a rare condition characterized by 
the shortage of limbal stem cells in the eye resulting in corneal conjunctivalization, 
corneal opacity, visual impairment and even blindness. Recently, the first advanced 
therapy medicinal product (ATMP) containing stem cells (GPLSCD01) has been rec-
ommended for approval by EMA in moderate-severe LSCD due to chemical or physi-
cal burn. A Cost Effectiveness Analysis (CEA) was performed, from a public payer 
perspective, to compare GPLSCD01 in LSCD with conservative treatment, given that, 
currently, no other medicinal product is approved for this disease. METHODS: We 
analyzed visual acuity and symptoms from 99 patients (average age 46.8 yrs.) treated 
with GPLSCD01; data were taken from a retrospective, case-series, non-randomized, 
non-controlled, multicenter clinical study (HLSTM01), covering up to 10 years fol-
low-up. LSCD-impaired visual acuity and symptoms such as pain, burning and 
photophobia were used in the model to assess the QoL associated with the condi-
tion, and Quality Adjusted Life Years (QALY) to compare the outcomes of GPLSCD01 
treatment versus conservative management, in a similar patient pool. RESULTS: 
Patients under conservative treatment had between 10.29 and 17.24 QALYs, depend-
ing on LSCD severity, whereas patients treated with GPLSCD01 showed between 
15.93 and 22.49 QALYs, with a total utility gain between 5.25 and 6.04 QALYs in the 
GPLSCD01 group, this result being already discounted by 3.0%, in compliance with 
National Institute for Health Care Excellence (NICE) guidelines. Due to the utility 
gain, GPLSCD01 would meet NICE conventional ICER thresholds (20,000 – 30,000 GBP/
QALY) up to a treatment cost of 150,000 GBP. CONCLUSIONS: GPLSCD01 is a regen-
erative medicine, offering long-term, potentially life-long effectiveness after single 
administration. This CEA shows that GPLSCD01 in moderate-severe LSCD provides a 
significant gain in QALYs compared to conventional, conservative management of 
the condition, balancing, from a payer perspective, initial higher acquisition costs.
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OBJECTIVES: The cost of lost productivity associated with chronic fatigue has 
been estimated to be more than £75 million per year in the U.K. Cognitive behav-
ioral Therapy (CBT) based fatigue self-management (FSM) has been shown to 
be effective in reducing fatigue symptoms. This study aimed to examine the 
cost-effectiveness of a home-based CBT-FSM intervention as compared to usual 
care. METHODS: 137 Primary care patients between 18 and 65 years of aging who 
had at least six months of persistent fatigue were randomized into either home-
based CBT-FSM intervention (n= 89, 45 with actigraph and web diaries and 44 with 
pedometer and paper diaries) or usual care (n= 48). All patients were followed for 12 
months post-treatment. Effectiveness was measured by the Fatigue Severity Scale 
(FSS) and health care resource use was measured by a utilization diary. Resource 
use categories included provider visits, diagnostic tests, prescription medication 
use, and use of emergency room, hospital, informal care, and days of lost work. We 
used ordinary least squares model and generalized linear model to estimate the 
treatment effect on effectiveness and health care expenditures, respectively. Cost-
effectiveness was measured by the incremental cost-effectiveness ratio (ICER) and 
net monetary benefit. RESULTS: The sample had a mean age of 48.5 years and 
most patients were female (88.3%). Baseline characteristics were similar between 
the intervention and control groups. Adjusting for baseline characteristics, the 
intervention had a small non-significant effect on FSS (-0.16, p= 0.32) and total 
expenditures (0.09, p= 0.32), resulting an ICER of 388 (bootstrapped 95% CI: -16463, 
17239). Cost-effectiveness acceptability curve showed that CBT-FSM had an 85% 
probability of being cost-effective if societal willingness-to-pay for each 1 point 
reduction on the FSS. CONCLUSIONS: The intervention did not appear to be cost-
effective as compared to usual care. The home-based intervention needs to be 
modified to maintain effectiveness achieved in prior interventions delivered by 
training professionals.
PSY39
CoSt-EffECtivEnESS of rituximab vErSuS CalCinEurin inhibitorS for 
rEfraCtorY mYaSthEnia graviS
Georgieva M.1, Wheeler S.1, Howard Jr. J.F.2
1Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, 
NC, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: Myasthenia gravis (MG) is a rare autoimmune disorder characterized 
by exacerbations and remissions. The costs of managing MG are higher than those 
of many other chronic neurological diseases and there are no studies evaluating 
the cost-effectiveness of treatment alternatives for refractory MG in patients who 
failed to respond to at least two successive immunosuppressive drugs. This study 
aimed to assess the incremental costs and benefits of rituximab, cyclosporine, 
and tacrolimus in the treatment of refractory MG. METHODS: We used a Markov 
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likely to start with combination pharmacotherapy. Patients who are older than 65, 
and those who have hypertension were less likely to start with combination pharma-
cotherapy. CONCLUSIONS: Patients on combination were more likely to switch, less 
likely to discontinue than mono-pharmacotherapy. Age, gender, and co-morbidities 
were predictors of receiving combination pharmacotherapy in DPN patients.
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OBJECTIVES: Patients with specialty conditions are faced with a unique set of chal-
lenges in regard to being adherent to their medications. One-on-one pharmacist 
counseling from the comfort of the patient’s home can be an innovative and impact-
ful intervention that can lead to improved adherence for specialty patients. This 
study analyzes the impact on adherence after an initial video conferencing session 
between pharmacist and patient at the start of treatment. METHODS: Patients new 
to therapy receiving a video conferencing session from the BriovaRx® specialty 
pharmacy from April 1, 2013 – May 31, 2014 were included in the analysis. The com-
parison group consisted of non-BriovaRx® patients that were also new to therapy 
during this timeframe and continuously eligible from October 1, 2012 – November 
30, 2014. The two groups of patients were matched on age, gender, and therapy. 
Adherence as measured by cumulative medication gap (CMG) was measured for 
both groups for 180 days after the start of treatment. The odds ratio was computed to 
assess the likelihood of a patient having an adherence greater than or equal to 80% 
with and without the video consultation. RESULTS: There were a total of 77 patients 
who received a video consultation and 117 total drug regimens. The distribution 
of disease states included: 25% hepatitis C, 22% rheumatoid arthritis, 18% multiple 
sclerosis and 35% other specialty conditions. The average age of patients receiving 
a consult was 46 with 56% female. The control group consisted of 1,465 patients and 
1,736 total drug regimens. Patients had significantly higher odds of being adherent 
if they received a video consult (OR= 2.04; 95% CI, 1.02-4.07). CONCLUSIONS: This 
study highlights the benefit that video consultations can have on the adherence of 
specialty pharmacy patients. This is especially important given the high cost and 
complex management of specialty medications.
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Wang V, Hanger M, Woyczynski M, Vaughan T, Wicks P PatientsLikeMe, Cambridge 
MA, USA. OBJECTIVES: (1) To understand the utility of using patient-reported data 
from an online Systemic Lupus Erythematosus (SLE) community for research, 
and (2) to understand the experience of living with SLE, including symptoms and 
treatments in a real-world environment. METHODS: Drawing on data captured by 
PatientsLikeMe, we explored reported patient symptoms, side-effects, treatments, 
and reasons for stopping treatment. We generated Kaplan-Meier curves of treatment 
duration for patients reporting particular side effects. Finally, to infer additional 
symptom and treatment factors that were important to SLE patients, we analyzed 
free text in patient forums and profiles. RESULTS: At the time of the research, 
PatientsLikeMe was being used by 5,714 SLE patients. With 2,570 PLM members with 
SLE (45%) reporting symptoms, lower back pain (53%), fatigue (52%), and joint pain 
(45%) were most likely to be rated as severe. In Forums, patients discuss pain, both 
general and localized, more than other frequently-measured symptoms, such as 
malar rashes. Of 5,026 members (88%) reporting treatments, hydroxychloroquine 
(73%), prednisone (63%), and OTC Naproxen (41%) were the most commonly used. 
Azathioprine, naproxen, and belimumab treatments were most often abandoned 
due to lack of efficacy, whereas hydroxychloroquine and methotrexate were more 
often abandoned due to side-effects. CONCLUSIONS: This study supports the ability 
of an online platform to capture important information on patient experience of 
disease and treatment, particularly in a poorly understood area such as lupus. Given 
the severity of side effects and abandonment of treatments, there is unmet need in 
SLE treatment. Clinical trials have often focused on easily measurable endpoints 
(e.g., rashes), but symptoms such as pain and fatigue are worthy of deeper study. 
Research that reflects the the most common and severe symptoms will encourage 
development of higher-value lupus treatments.
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OBJECTIVES: Utility values are required to conduct cost-utility analyses for the eco-
nomic evaluation of novel therapies. While preference-based utility measures, such 
as the EQ-5D, are preferred by healthcare payers, they may inadequately capture 
condition-specific differences in health-related quality of life (HRQoL) or may not be 
available from clinical trials. Utility values for patients with polycythemia vera (PV), 
a myeloproliferative neoplasm (MPN), are not available in the literature; however, the 
PV RESPONSE trial collected EORTC QLQ-C30 and MPN-SAF data. The objective of the 
current study was to estimate utility values for PV patients using existing mapping 
algorithms. METHODS: EORTC QLQ-C30 data from the RESPONSE trial were mapped 
onto the EQ-5D using published mapping algorithms for various cancers (e.g., mul-
tiple myeloma, breast, gastric, esophageal). Utility values were also estimated using 
the MF-8D, a condition-specific preference-based measure that was developed for 
myelofibrosis, another MPN, using both the EORTC QLQ-C30 and MF-SAF. Utility 
values obtained from the various mapping algorithms were compared. RESULTS: 
At baseline in the RESPONSE trial, utility values calculated for PV patients using 
OBJECTIVES: Chronic back pain is a common health problem which is associated 
with considerable costs in United States. The largest categories for pain therapy 
costs include NSAID analgesics and opioids. However there has been limited 
evidence outlining the effectiveness in terms of quality of life of patients taking 
these pain medications for treating chronic back pain.Objective of this study is to 
perform a cost-utility analysis of chronic back pain patients using NSAIDS versus 
those using opioids alone and/ or combination opioid analgesics. METHODS: This 
cross sectional, observational, cost utility study was conducted using the Medical 
Expenditure Panel Survey database. Adult’s ≥ 18 years with chronic back pain diag-
nosis (identified by ICD-9 –CM codes) for atleast 3 consecutive rounds were included 
in the study. The study was conducted from a payer’s perspective and only the 
direct costs were included . Utility was measured using SF-6D scores from the SF-12 
questionnaire. RESULTS: 1340 chronic back pain patients were identified from 2012 
MEPS database, of which 53% (n= 704) were in NSAIDS group and 47% (n= 636) were 
in opioids group. The total mean cost of NSAIDs group was found to be $ 8005.3 
while the total mean cost of opioids group was found to be $12475, 99. The QALYs 
of both the groups was almost the same with the mean QALY score of NSAIDs group 
being 0.645 and the opioids group being 0.615. CONCLUSIONS: Preliminary analysis 
showed that for the extra cost spent on Opioids, the effectiveness was seen to be 
almost the same as those taking NSAIDS. This may be because of the severe adverse 
events associated with the use of opioids which may reduce the quality of life of 
patients. Further research needs to be conducted by considering other pharmaco-
logical agents used to treat back pain and finding the most cost effective treatment.
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OBJECTIVES: Tuberous sclerosis complex (TSC) is a rare genetic disorder associated 
with angiomyolipomata (non-malignant kidney lesions) in the majority of patients. 
Angiomyolipomata increase in size over time, present risk of acute hemorrhage, and 
can lead to progressive chronic kidney disease (CKD). Our objective was to document 
the association between angiomyolipomata and CKD, including the impact on health 
care resource utilization (HCRU) and health care costs. METHODS: This retrospective, 
longitudinal cohort study used medical chart data from patients with TSC treated at 
a specialty center in the Netherlands from January 1990 to April 2012. Patients were 
followed longitudinally and classified into open cohorts based on their CKD stage 
(estimated from serum creatinine levels) and size and number of angiomyolipomata. 
Average glomerular filtration rates (GFR) and the proportions of patients reaching 
advanced CKD stages were compared with a non-TSC reference population. HCRU 
rates and health care costs (2012€ ) per patient per year (PPPY) were compared across 
cohorts. RESULTS: 369 patients were included (median [mean] follow-up time 15.4 
[14.3] years). Compared with the non-TSC reference population, the decline in kidney 
function with age was steeper for patients with TSC (mean change in GFR/year= -1.53 
vs. -0.94 mL/min/1.73 m2), and more patients with TSC reached CKD stage 3 or higher 
(16% vs. 3% of patients < 70 years old). Compared with CKD stage 1, CKD stages 2 to 5 
were associated with larger and more numerous angiomyolipomata, higher overall 
HCRU rates (rate ratios= 1.5 to 2.3, P≤ 0.01), and higher health care costs (incremen-
tal costs= € 737 to € 30,641 PPPY, P≤ 0.004). CONCLUSIONS: Our results suggest that 
impaired kidney function associated with angiomyolipomata imposes a significant 
burden and remains a key concern in patients with TSC. Treatments that slow the rate 
of kidney function decline in patients with TSC may substantially reduce the HCRU 
and costs associated with CKD and angiomyolipomata.
SYStEmiC diSordErS/ConditionS – Patient-reported outcomes & Patient 
Preference Studies
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OBJECTIVES: To compare patient characteristics between DPN patients receiv-
ing mono-pharmacotherapy and those receiving combination pharmacother-
apy. METHODS: A patient cohort was identified diagnosed with DPN during 2006-2013 
in Inovalon’s MORE2® registry, a healthcare data warehouse with national medi-
cal/pharmacy claims, continuously enrolled for at least 18 months. Patients were 
included if they were ≥ 18 years at the time of their first DPN prescription for tricyclic 
antidepressant (TCAs), opioids, duloxetine, gabapentin, pregabalin, or lidocaine. They 
were classified as having mono- or combination pharmacotherapy (time between 
the first and second medicine was within 30 days). If there was 60-day prescription-
filled gap, the prescription was classified as discontinued. Switch or add-on groups 
were categorized based on continuation of the index medicine. A simple proportional 
hazards model was conducted for comparing time to discontinuation, switch, or 
add-on. Multiple logistic regression was used for identifying predictors of combi-
nation pharmacotherapy. RESULTS: There were 7,145 patients on mono-pharma-
cotherapy, and 421 patients on combination pharmacotherapy. The top three index 
medicines were gabapentin (55.7%), opioids (13.1%), and pregabalin (12.9%) in the 
mono-pharmacotherapy group, and opioids+ gabapentin (27.1%), TCAs+ gabapen-
tin (17.6%), and duloxetine+ gabapentin (8.6%) in combination group. Patients on 
combination pharmacotherapy were 57% less likely to discontinue than patients 
on mono-pharmacotherapy (95%CI = 0.34-0.54, p< 0.001), and 916% more likely to 
switch than patients on mono-pharmacotherapy (95%CI = 8.30-12.43, p< 0.001).There 
was no statistically significant difference in time to add-on (p= 0.069). Patients who 
are female, with > 7 co-morbidities, and who had depression, or arthritis were more 
